About Shanghai B&C Pharmaceutical
Shanghai B&C Pharmaceutical is a company based in Xuzhou (China) founded in 2010 by Zhiwei Fu and Fu Zhiwei. Shanghai B&C Pharmaceutical has raised $130.52 million across 5 funding rounds from investors including CGP Investment, Zhongping Capital and Guokai Technology Venture Investment. Shanghai B&C Pharmaceutical operates in a competitive market with competitors including Inpria and Jiangsu Boyan Electronic Technology, among others.
- Headquarter Xuzhou, China
- Founders Zhiwei Fu, Fu Zhiwei
- Stage Unicorn
-
Sectors
Chemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$130.52 M (USD)
in 5 rounds
-
Latest Funding Round
$87.02 M (USD), Series C
Apr 24, 2023
-
Investors
CGP Investment
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Shanghai B&C Pharmaceutical
Shanghai B&C Pharmaceutical has successfully raised a total of $130.52M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $87.02 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Shanghai B&C Pharmaceutical
Shanghai B&C Pharmaceutical has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include CGP Investment, Zhongping Capital and Guokai Technology Venture Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Shanghai BC Pharmaceutical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Shanghai B&C Pharmaceutical
Investment portfolio details for Shanghai BC Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Shanghai BC Pharmaceutical
Detailed financials for Shanghai BC Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Shanghai B&C Pharmaceutical Comparisons
Peer comparison for Shanghai BC Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Shanghai B&C Pharmaceutical
Shanghai B&C Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inpria and Jiangsu Boyan Electronic Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Inorganic photoresists and thin films for semiconductor lithography are supplied.
|
|
| Locked | Locked | Locked |
Photoresist products are manufactured in Wuxi, China, since 2014.
|
Detailed competitors of Shanghai BC Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Shanghai B&C Pharmaceutical
Complete news archive for Shanghai BC Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shanghai B&C Pharmaceutical
Shanghai B&C Pharmaceutical was founded in 2010 and raised its 1st funding round 11 years after it was founded.
Shanghai B&C Pharmaceutical is headquartered in Xuzhou, China. It is registered at Xuzhou, Jiangsu, China.
Shanghai B&C Pharmaceutical is a funded company, having raised a total of $130.52M across 5 funding rounds to date.
Shanghai BC Pharmaceutical was established in 2010 in Xuzhou, China, focusing on the semiconductor sector. Photoresists, monomers, resins, and associated chemicals are produced for industrial use. A platform is offered to support photoresist manufacturing processes. Operations center on supplying raw materials to clients in the electronics and chemical industries, with distribution primarily in Asia.
Shanghai B&C Pharmaceutical's top competitors include Inpria and Jiangsu Boyan Electronic Technology.
Shanghai B&C Pharmaceutical has 11 investors. Key investors include CGP Investment, Zhongping Capital, Guokai Technology Venture Investment, NEW HOPE CAPITAL, and V Fund.
The valuation of Shanghai B&C Pharmaceutical is $1B as of Apr 2023.